For the pharma industry, the rise of healthcare content creators – both healthcare professionals (HCPs) and patients – ...

Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with primary biliary cholangitis (PBC). The oral peroxisome ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...

Researchers from the Institute of Cancer Research (ICR) have highlighted the potential benefits of treating bladder cancer with personalised radiotherapy. More than 130,000 patients are treated on the ...

See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and ...